Your session is about to expire
← Back to Search
Chemotherapy + Immunotherapy for Ovarian Cancer
Study Summary
This trial will test the effectiveness of adding nivolumab or a combination of nivolumab and ipilimumab to the standard chemotherapy treatment of Carboplatin and Paclitaxel for advanced high-grade serous cancers of ovarian, fallopian tube, or primary peritoneal origin.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the Food and Drug Administration given its stamp of approval to Carboplatin and Paclitaxel?
"As a Phase 1 clinical trial, the safety of carboplatin and paclitaxel has been limitedly studied. Our team at Power assigned it a score of 1 on our assessment scale."
For what therapeutic purposes is Carboplatin and Paclitaxel commonly prescribed?
"Carboplatin and Paclitaxel can be used to treat menacing neoplasms, incurable melanoma, and squamous cell carcinomas."
How many patients have enrolled in this experiment?
"This trial is no longer open for recruitment. It was first posted on August 4th 2017 and its last update took place April 13th 2022. Currently, 131 studies are looking to enrol patients with Fallopian tubes issues while 1,872 trials require participants for Carboplatin/Paclitaxel treatments ."
Are there vacancies for individuals to join this scientific experiment?
"This study, which went live on 8/4/2017 and was last updated on 4/13/2022, is not presently recruiting any additional participants. Nevertheless, there are over two thousand other medical trials currently in the process of enrolment."
Share this study with friends
Copy Link
Messenger